It has been recently documented by cardiomyocyte-specific gene transfer or knockout that, apart from the well-known role of VEGFB in physiological angiogenesis and adaptive cardiac muscle hypertrophy, this growth factor plays a role in reprogramming myocardial metabolism [45,46,47], e.g., in old mice, heart-specific overexpression of VEGFB induced compensatory, cardioprotective hypertrophy [46] and improved insulin sensitivity through downregulation of cardiac lipoprotein lipase (LPL) activity [47]. The gene discussed is LPL; the disease is Skeletal muscle hypertrophy.